Lipidor’s New Share Issue Achieves 540 % Subscription

Report this content

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq First North Growth Market. The issue of approximately SEK 25.2 million was subscribed at SEK 136 million, corresponding to a subscription rate of circa 540%. Through the share issue, the company will add circa 1,150 new shareholders.

CEO Ola Holmlund comments

“We’re in the final phase of a Phase III study and have several projects coming to the clinic over the next few years. The great interest in investing in our business matches the interest we have seen among partners and patients for our drug candidates. Supported by this successful share issue, we can increase the rate of development for our value-creating work,” says Lipidor's CEO Ola Holmund.

Subscription and allotment

The issue of approximately SEK 25.2 million was subscribed at SEK 136 million, including a subscription commitment of SEK 18.2 million, which corresponds to a subscription rate of circa 540%. Through the share issue, the company adds circa 1,150 new shareholders. This means that 4,200,000 shares and 2,100,000 TO1 warrants will be issued. The company is thus provided with issue proceeds totaling SEK 25.2 million before deduction of issue costs, which are estimated at approximately SEK 2.5 million. The warrants may provide the Company an additional minimum SEK 18.9 million and maximum of SEK 25.2 million by November 2020.

Unfortunately, due to the strong interest, not all subscribers have been awarded. Allocation of units under the new share issue, is in accordance with the principles stated in the memorandum published on 26 August 2019.

Preliminary schedule

Settlement date: 19 September 2019
Expected first day of trading: 27 September 2019 for both shares and TO1 warrants

Shares and share capital

After the listing issue, the share capital amounts to SEK 1,179,200 divided into 23,584,000 shares. Registration of the issue is expected to take place at the Swedish Companies Registration Office (Bolagsverket) in September 2019.


Corpura Fondkommission AB is the financial advisor in connection with the Offer and the Company's Certified Adviser. The legal advisor to the Company in connection with the issue was Fredersen Advokatbyrå AB. Aqurat Fondkommission AB acted as issuer.


The information above was provided by Lipidor AB according to EU Market Abuse Regulations. The information was provided, through the below contact person, for publication on 16 September 2019 at 15:00 CET.

For more information, please contact

Ola Holmlund, CEO, Lipidor AB

Phone: +46 72 5070369



Certified Advisor

Corpura Fondkommission AB

Telephone: +46 76 8532822 


About Lipidor

Lipidor AB ( is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.


Documents & Links